Do You Need a License to Sell Peptides?

Short version: there is no single federal “peptide license” you apply for and hang on the wall. If you were hoping this post would tell you which government form makes you a legal peptide seller, that form does not exist.

That is also where most of the confusion starts. People hear “no license required” and conclude there are no requirements. That is wrong in a way that gets operators in trouble. The absence of a dedicated license does not mean the absence of rules. It means the rules live somewhere other than a licensing counter, and if you do not understand where, you can do everything you think is required and still be exposed.

This is the honest operator answer. It covers what you actually need to open the doors, where the real legal risk sits, and why the thing that determines your exposure is not a piece of paper you are missing. It is general information for people building in this space, not legal advice, and the consult-an-attorney line at the end is not filler.

The short answer

As of this writing, selling research compounds for research use only in the United States does not require a specific federal license issued for that activity. Research peptides as a class are not scheduled controlled substances, so you are not applying for a controlled-substance registration the way a business handling scheduled drugs would.

What you do need is the ordinary infrastructure of a legitimate business, plus a strict discipline about how you describe what you sell. The paperwork is the easy part. The discipline is what separates the operators who last from the ones who get a warning letter.

Here is the structure the rest of this post walks through:

• The business-and-tax setup that any real operation needs (entity, tax ID, permits).
• Why the compounds themselves are not the source of your legal exposure.
• Why the way you market is the source of your legal exposure.
• How state law adds variation on top of the federal picture.
• What the 2026 FDA compounding-list changes did and did not do.

What you actually need to open the doors

None of these is a “peptide license.” All of them are things you need anyway to run a legitimate operation, and skipping them creates problems that have nothing to do with the products.

The LLC and EIN come first because everything else depends on them. Your wholesaler will ask for the entity and tax ID before opening an account, your bank will ask for both, and your state sales-tax registration will reference them. File the entity in your home state unless you have a specific reason not to. The “form in Delaware or Wyoming” advice is aimed at venture-backed startups, not a bootstrapped reseller.

The sales-tax and resale-permit piece is where a lot of new operators get sloppy. A resale certificate is not a license to sell peptides. It is a tax document that says the inventory you buy is for resale, so your wholesaler does not charge you sales tax on it, and it obligates you to collect and remit sales tax where you have a nexus. That is a general commerce requirement. It applies to a peptide reseller the same way it applies to someone reselling office chairs.

We walk through the full entity-and-financial setup, with the specific services worth using, in how to start a peptide company.

The compounds are not where your exposure is

Here is the part that surprises people. You can have every permit above perfectly in order and still create serious legal exposure, because the exposure does not come from the products or a missing license. It comes from what you say the products are for.

This is the single most important thing to understand before you sell anything in this category. We cover it in depth in are peptides legal, and it is worth reading that post in full, but the core of it is this: under the Federal Food, Drug, and Cosmetic Act, whether something is regulated as a “drug” turns substantially on its intended use, and the FDA reads intended use from your labeling, your advertising, your promotional material, and the circumstances of the sale. The governing regulation is 21 CFR 201.128.

Two operators can ship the identical compound from the identical batch and be in completely different legal positions.

The first lists the compound with its molecular weight, purity spec, storage conditions, and a research-use-only statement. No dosing. No claims about what it does in a person. No comparison to a prescription product.

The second lists the same compound under a headline about fat loss, includes an administration schedule, references a trademarked pharmaceutical brand name, and posts customer photos.

The second operator has, in regulatory terms, marketed an unapproved new drug and misbranded it. The molecule was never the issue. The marketing was. That is why nearly every FDA warning letter in this category cites the same two theories, unapproved new drug and misbranding, and both are about the marketing rather than the chemistry.

“Research use only” is not a magic phrase that creates a safe harbor. It is a description of what the product is being sold for, and it only holds if the entire operation matches. A footer disclaimer paired with dosing charts in the product descriptions is not compliance. It is a contradiction any reviewer will resolve against you. The research framing has to be true across the whole site, every email, every ad, and every social post, or it is not doing anything for you.

This is why the answer to “what license do I need” is less important than the answer to “how do I describe my products.” You control the second one completely, and it is what determines your legal exposure.

Research peptides are not controlled substances

A common worry among new operators is that they are one regulatory step away from handling something like a scheduled narcotic. For research peptides as a class, that is not the current picture.

The Controlled Substances Act sets up five schedules of drugs with escalating restrictions and criminal penalties for unregistered distribution. Anabolic steroids sit on Schedule III, placed there by the Anabolic Steroid Control Act of 1990 and expanded by later statutes in 2004 and 2014. The steroid class itself is scheduled, not just individual named molecules.

Research peptides have no equivalent. There is no Peptide Control Act, and the compounds commonly discussed in this category are not listed on any federal schedule, individually or as a class. That is a genuine and meaningful difference from steroids, and it is why the setup for a research-compound reseller does not involve a controlled-substance registration.

One separate federal carve-out is worth knowing because it is often missed: human growth hormone is restricted on its own under 21 U.S.C. 333(e), which makes distributing hGH for non-approved uses a federal offense even though hGH is not scheduled. That statute applies to somatropin itself, not to the broader class of research peptides that sometimes get discussed alongside it. If your planned catalog touches that specific molecule, that is an attorney conversation before anything else.

The FDA 503A compounding angle, stated accurately

You will run into news coverage suggesting the FDA “banned” a list of peptides, and you should understand exactly what that coverage is describing, because it is easy to draw the wrong conclusion.

Sections 503A and 503B of the FD&C Act govern compounding pharmacies and outsourcing facilities, not research-use-only resellers. A compounder can work with a bulk drug substance under certain conditions, one of which is that the substance appears on an FDA-evaluated list. The FDA sorts nominated substances into categories, and in 2023 it placed a set of peptides, BPC-157 being the best-known, into Category 2, meaning it had identified significant safety risks for compounding purposes. That blocked compounding pharmacies from using those substances while the placement stood.

Then the position moved. In April 2026, after the compounding nominations were withdrawn and HHS confirmed the change, the FDA removed twelve peptides from Category 2, including BPC-157 and the thymosin beta-4 fragment sold as TB-500, and referred several of them to its Pharmacy Compounding Advisory Committee later that year for review. Two things about this matter for an operator:

• It governs compounding, not research-use-only resale. The 503A framework is about what a compounding pharmacy may prepare for patients. It is a different activity from supplying an unapproved research compound labeled for laboratory use. The list changes did not create or remove a “license to sell peptides,” because that is not what the list is about.
• Removal from Category 2 is not approval. The substances were not moved to an approved list. Compounding them still sits outside the FDA’s interim enforcement-discretion posture while the review runs. Reading “removed from Category 2” as “FDA approved” is exactly the kind of overstatement that gets operators into trouble in the other direction.

The lists move, in both directions, and they have moved more than once in recent years. Anyone whose plans depend on the compounding status of a specific compound should check the FDA’s current published list rather than rely on any blog post, including this one.

State law adds variation

Federal law is not the whole picture. States maintain their own controlled-substance schedules and can schedule substances the federal government has not. States also run their own consumer-protection statutes, and state attorneys general have brought actions in this category independently of federal regulators.

The one that catches operators off guard is wholesale drug distribution licensing. In most states, distributing drugs at wholesale is a licensed activity, and whether that regime reaches a given operation depends on how the products are classified and marketed. A business model that is fine in one state may carry a licensing requirement in another. This is genuinely an attorney question, and it is worth answering before you open an account rather than after you have inventory on the shelf.

Practically, this means “do you need a license to sell peptides” does not have one national answer. The federal answer is no dedicated license. The state answer is: it depends on your state, your classification, and your marketing, and you should confirm it locally.

Where a license does not help you, and what does

Notice what all of this adds up to. The permits you can obtain, entity, tax registration, resale certificate, are real requirements, but none of them protects you from the thing most likely to end a peptide business. The failure mode in this category is almost never “operator lacked a license.” It is “operator’s marketing drifted into disease or body-composition claims and drew a warning letter.”

So the operator checklist that actually protects you looks like this:

1. Stand up the entity, EIN, bank account, and tax permits. Ordinary business hygiene.
2. Write every product page, email, and ad in research-use-only terms and keep them there. This is the load-bearing one.
3. Never provide dosing, administration, or use-in-a-person guidance anywhere on the site.
4. Never use trademarked pharmaceutical brand names to sell an unapproved compound.
5. Confirm your state’s wholesale-distribution and consumer-protection posture with a local attorney.

Payments are their own layer that sits alongside all of this, since no mainstream card processor will approve the category. We cover the realistic stack in peptide payment processors, and the sourcing side in the complete guide to peptide wholesale.

Frequently asked questions

Do you need a license to sell peptides in the US?

As of this writing, there is no dedicated federal license for selling research compounds for research use only. You do need the ordinary infrastructure of a legitimate business: an LLC, an EIN, a business bank account, and the appropriate state sales-tax and resale permits. Some states also regulate wholesale drug distribution, which can apply depending on classification and marketing. This is not legal advice.

Is a resale certificate the same as a peptide license?

No. A resale certificate is a tax document. It lets you buy inventory for resale without paying sales tax on it and obligates you to collect and remit sales tax where you have a nexus. It says nothing about the products being peptides and does not authorize or prohibit selling them. It is a general commerce requirement.

Are research peptides controlled substances?

As a class, they are not listed on any federal drug schedule, which is a real distinction from anabolic steroids on Schedule III. Human growth hormone is restricted separately under 21 U.S.C. 333(e) even though it is not scheduled. Individual state schedules can differ from the federal list, so a specific compound in a specific state is worth confirming.

Did the FDA ban peptides in 2026?

No. In April 2026 the FDA removed twelve peptides, including BPC-157 and TB-500, from Category 2 of its 503A bulk-substances evaluation. That framework governs compounding pharmacies, not research-use-only resale, and removal from Category 2 is not approval. Reporting that collapses these compounding-list changes into “banned” or “approved” is wrong in both directions.

What actually gets peptide sellers in legal trouble?

Marketing, not a missing license. The recurring triggers in FDA and FTC actions are disease and body-composition claims, dosing and administration instructions aimed at consumers, use of trademarked pharmaceutical brand names, and human testimonials. Operators who describe compounds in research terms without those elements are in a materially different position.

The bottom line

There is no single license that makes you a legal peptide seller, and there is no single license whose absence makes you an illegal one. What there is: a normal business setup you have to complete, a set of state requirements that vary, and one discipline, keeping every word of your marketing in research-use-only terms, that matters more than any permit. The operators who last treat that discipline as the actual license, because functionally it is.

This is general information about how the regulatory structure is built. It is not legal advice, it does not account for your state or your specific facts, and the rules in this category have changed repeatedly in recent years. Consult a qualified attorney before making decisions about opening or operating a business in this space.

If you want a sanity check on your specific situation before you commit, we do a free intro call with founders thinking about entering the category. Details at wwpeptides.com/vip-services/.

Further reading

• Are peptides legal? US rules explained
• How to start a peptide company
• Peptide wholesale: the complete guide
• Payment processors for peptide merchants